Bacterial community interactions during chronic respiratory disease
This difference was recently found to be due to sex differences in ferroptosis
Finally, the most important reminder of all is a regulatory and safety one: the peptides discussed here are, in most jurisdictions, classified for research use only and are not approved for human use by the FDA or EMA
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Clinical trials showed 15 to 24% body weight loss over one year